Encorafenib/Cetuximab Plus FOLFIRI Improves PFS in BRAF V600E-Mutant mCRC
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers: In an unforeseen development, the FDA has placed a partial clinical hold on the Lorigerlimab trial, attributing this decision to serious safety events.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: The medical fraternity is intensifying efforts to refine management strategies to handle specific toxicities associated with Melanoma.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: In another significant advancement, FDA has granted fast track designation to SRN-101, a promising new treatment for high-grade gliomas.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: A novel molecule has shown early positive signs in the treatment of multiple myelomas in the preliminary stages.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: A fresh comparative study has been launched focusing on the quality of life outcomes concerning OPSCC treatment with Protons as opposed to Photons.
